Vickers Vantage Corp. I (NASDAQ: VCKA) announced this afternoon that its shareholders have approved its combination with commercial biopharmaceutical company Scilex, a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE), at a special meeting held yesterday, November 9.
At the meeting, holders of 10,198,275 shares were present by proxy or in person, representing 77.398% of the total Vickers ordinary shares outstanding. The business combination was approved with 8,202,588 votes in favor of it, and 1,781,233 votes against the proposal.
The press release did not divulge redemption figures, but VCKA traded below its trust value of $10.10 throughout its redemption deadline on November 7. VCKA opened today at $9.03, but has dropped 15% to $8.50, while SRNE has climbed approximately 15% on the announcement to $1.62.
Nonetheless, shares of the common stock will trade on the Nasdaq Capital Market on Friday, November 11, under the ticker symbol “SCLX”.
Vickers Vantage I originally announced its $1.64 billion combination with Scilex on March 18, 2022. The Palo Alto-based company focuses on the development and commercialization of non-opioid pain management products for treatment of acute and chronic pain.
ADVISORS
- Loeb & Loeb, LLP is serving as legal counsel to VCKA.
- Paul Hastings LLP is serving as legal counsel to Scilex.
Vendome Acquisition Corporation I (NASDAQ:VNMEU) announced the pricing of its $200 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “VNMEU”, Wednesday, July 2, 2025. The new SPAC plans to focus its search on target business in the consumer sector operating in North America, Southeast Asia, and Europe....
Origin Investment Corp. I (NASDAQ:ORIQU) announced the pricing of its $60 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “ORIQU”, Wednesday, July 2, 2025. The new SPAC aims to mount a broad search for a target with a strong management and both revenue and earnings growth potential....
1RT Acquisition Corp. (NASDAQ:ONCHU) announced the pricing of its $150 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “ONCHU”, Wednesday, July 2, 2025. The new SPAC plans to target company in the digital asset ecosystem involved in the creation, storage, exchange or management of such assets, whether...
D. Boral ARC Acquisition II Corp. (NASDAQ:ARBCU) has filed for a $250 million SPAC to give underwriter D. Boral a second in-house SPAC to pursue deals with. The new SPAC offers investors a 1/2 warrant and an initial 18-month time frame to complete a deal. D. Boral II’s sponsor may automatically extend this once by...
Ribbon (NASDAQ:RIBB) has entered into a definitive agreement to combine with Japanese biotech firm DRC Medicine at a pro forma equity value of $422 million. Tokyo-based DRC Medicine manufactures reusable anti-bacterial and anti-allergen wearables and aims to go deeper into the medical device and pharmaceutical space. Transaction Overview Ribbon is expected to provide $50.4 million...